News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Andrew Hertler, MD, FACP

Articles by Andrew Hertler, MD, FACP

Ander Hertler, MD | Image credit: Evolent

Clinical Trials Must Represent Those Who Will Receive Therapy

ByAndrew Hertler, MD, FACP

February 19th 2025

CAR T-cell therapy | Image credit: Getty Images Science Library

Whither CAR T? Will the FDA Being Under the Hood and the Availability of Bispecifics Make These Therapies Less Attractive?

BySang Chau, PharmD, BCOP,Justin Tse, PharmD, BCOP,Amy VanGalder, PharmD, BCOP,Garrick Wong, PharmD,Terra Wonsettler, PharmD, MBA,Andrew Hertler, MD, FACP

June 12th 2024

Genetic Testing in Cancer Care: Considerations for a Condition-Based Approach

ByAndrew Hertler, MD, FACP,Sadie Dobrozsi, MD, MS

February 14th 2024

Latest Updated Articles

Whither CAR T? Will the FDA Being Under the Hood and the Availability of Bispecifics Make These Therapies Less Attractive?
Published: June 12th 2024 | Updated:
Genetic Testing in Cancer Care: Considerations for a Condition-Based Approach
Published: February 14th 2024 | Updated:

Trending on AJMC

Price Transparency With Gaps: Assessing the Completeness of Payer Transparency in Coverage Data

T-DXd Delivers Strong Breast Cancer Outcomes Across Groups

Camizestrant-Related Photopsia Mostly Mild, Nondisabling in Patients With Advanced Breast Cancer: Adam Brufsky, MD, PhD

Clinicians Cite Progress Tracking as Top Barrier in Value-Based Care

Bispecific Antibodies for Multiple Myeloma in Community Oncology Are on the Rise: Ira Zackon, MD

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.